Literature DB >> 22669438

[Pharmacology of botulinum toxin drugs].

D Dressler1.   

Abstract

Botulinum toxin (BT) is used with remarkable success to treat various disorders caused by muscle hyperactivities or exocrine gland overactivity. Its use for treatment of non-muscular pain conditions is currently being explored. In Germany, BT type A is available as Botox®, Dysport® and Xeomin®, BT type B as NeuroBloc®. In aesthetic medicine they are called Vistabel®, Azzalure® and Bocouture®. Numerous other BT drugs are used worldwide. Often, their origin is dubious. BT drugs consist of botulinum neurotoxin, complexing proteins and adjuvants. Their manufacturing process is highly complex. BT drugs vary in many aspects. By no means are they generics. Clinically relevant differences include their potency labeling, antigenicity, presence of complexing proteins, storage conditions, pH value of the reconstituted drug and pharmaceutical preparation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22669438     DOI: 10.1007/s00106-012-2494-1

Source DB:  PubMed          Journal:  HNO        ISSN: 0017-6192            Impact factor:   1.284


  40 in total

1.  Presynaptic effects of botulinum toxin type A on the neuronally evoked response of albino and pigmented rabbit iris sphincter and dilator muscles.

Authors:  H Ishikawa; Y Mitsui; T Yoshitomi; K Mashimo; S Aoki; K Mukuno; K Shimizu
Journal:  Jpn J Ophthalmol       Date:  2000 Mar-Apr       Impact factor: 2.447

2.  Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins.

Authors:  M J Welch; J R Purkiss; K A Foster
Journal:  Toxicon       Date:  2000-02       Impact factor: 3.033

3.  OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial.

Authors:  S K Aurora; D W Dodick; C C Turkel; R E DeGryse; S D Silberstein; R B Lipton; H C Diener; M F Brin
Journal:  Cephalalgia       Date:  2010-03-17       Impact factor: 6.292

4.  Differential inhibition by botulinum neurotoxin A of cotransmitters released from autonomic vasodilator neurons.

Authors:  J L Morris; P Jobling; I L Gibbins
Journal:  Am J Physiol Heart Circ Physiol       Date:  2001-11       Impact factor: 4.733

5.  Changes in the electron microscopic structure of slow and fast skeletal muscle fibres of the mouse after the local injection of botulinum toxin.

Authors:  L W Duchen
Journal:  J Neurol Sci       Date:  1971-09       Impact factor: 3.181

6.  Extrafusal and intrafusal muscle effects in experimental botulinum toxin-A injection.

Authors:  R L Rosales; K Arimura; S Takenaga; M Osame
Journal:  Muscle Nerve       Date:  1996-04       Impact factor: 3.217

7.  Botulinum neurotoxin C1 cleaves both syntaxin and SNAP-25 in intact and permeabilized chromaffin cells: correlation with its blockade of catecholamine release.

Authors:  P Foran; G W Lawrence; C C Shone; K A Foster; J O Dolly
Journal:  Biochemistry       Date:  1996-02-27       Impact factor: 3.162

8.  Proteolysis of SNAP-25 by types E and A botulinal neurotoxins.

Authors:  T Binz; J Blasi; S Yamasaki; A Baumeister; E Link; T C Südhof; R Jahn; H Niemann
Journal:  J Biol Chem       Date:  1994-01-21       Impact factor: 5.157

9.  Inhibition of calcium-dependent release of noradrenaline from PC12 cells by botulinum type-A neurotoxin. Long-term effects of the neurotoxin on intact cells.

Authors:  C C Shone; J Melling
Journal:  Eur J Biochem       Date:  1992-08-01

10.  Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery.

Authors:  A B Scott
Journal:  J Pediatr Ophthalmol Strabismus       Date:  1980 Jan-Feb       Impact factor: 1.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.